Nanologica was founded in 2004 and is a nanotechnology company developing, manufacturing and selling nanoporous silica particles for applications within life science. Nanologica is world leading in controlling shape, porosity and surface characteristics of silica particles. This competency is applied in two business areas – drug development and chromatography, a separation technique used in drug development and drug production.
Better and cheaper medicine through porous silica.
We aim to make insulin available to more patients in need by reducing the production cost.
We are committed to leverage our technology platform to provide new treatments for patients with severe lung diseases.
Within the business area of Chromatography, Nanologica’s objective is to establish a fast-growing, sustainable, and profitable business by providing silica-based products for the analysis and purification of substances. The target is to lower the costs of medicines, with a focus on diabetes products.
Within the business area of Drug Development, Nanologica’s objective is to create long-term value with our own assets, as well as together with partners. The ambition is to bring innovation to the inhalation field in particular, by providing a platform for local delivery of medicines to the lung.
Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Spotlight Stock Market.